Black Diamond Therapeutics Inc
Company Profile
Business description
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
Contact
245 First Street
18th Floor
CambridgeMA02142
USAT: +1 617 252-0848
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
21
Stocks News & Analysis
stocks
Chart of the Week: BHP’s growth story faces a reality check
stocks
3 best ASX growth stocks to buy for the long term
stocks
The ASX data center stock flying under the radar
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,036.90 | 13.00 | -0.14% |
| CAC 40 | 8,329.77 | 52.66 | -0.63% |
| DAX 40 | 24,773.09 | 226.44 | -0.91% |
| Dow JONES (US) | 52,625.92 | 32.72 | -0.06% |
| FTSE 100 | 10,488.64 | 27.28 | -0.26% |
| HKSE | 25,008.60 | 327.50 | 1.33% |
| NASDAQ | 26,025.76 | 243.46 | -0.93% |
| Nikkei 225 | 66,835.54 | 1,915.97 | -2.79% |
| NZX 50 Index | 13,614.78 | 20.29 | -0.15% |
| S&P 500 | 7,544.22 | 28.18 | -0.37% |
| S&P/ASX 200 | 8,840.70 | 15.50 | -0.18% |
| SSE Composite Index | 3,882.41 | 73.17 | -1.85% |